X
Call Us Today! 904-350-1155 | info@firstcoasthealthsolutions.com

Tennessee DNA GeneticsTesting For Better Outcomes

3x as many people are addicted to and die from prescription narcotic pain medications than all illegal narcotics combined!

An estimated 2g0-30% of pain patients have an genetic opioid metabolic defect. (1)

2.2 million adverse drug events occur yearly with over 100,000 cases resulting in death. (2)

Pain medication abuse can be due to genetics.

Without testing your patients, your ability to predict your patients response is no better than 50/50 – just like flipping a coin. In comparison, this simple pain-free, needlefree, and blood-free cheek swab can identify patients’ drug metabolizing phenotypes for improved efficacy; decreased adverse effects; reduced drug interactions and increased treatment adherence.

Reduce the Guesswork When Prescribing

Determine a patient’s predisposition to metabolize the medications you prescribe to guide selection, dosing, and evaluation.

We now offer a simple test that you can administer to patients by taking a saliva sample from their cheek and sending it to our labs. We will provide valuable reports that will help you better manage your patients drug therapy and achieve better outcomes. Our pharmacogentic test reports categorize a patient into one of four metabolizer categories for each genetic pathway.

Ultra Rapid Metabolizers

have an increased risk of treatment failure from non-prodrugs* due to increased metabolism, and an increased risk of toxicity from prodrugs* due to excessive formation of active metabolites.

Extensive Metabolizers

Normal drug metabolism should be expected.

Intermediate Metabolizers

Often a reduced dose of non-prodrugs is suggested with close monitoring for adverse drug events. Administration of inhibitors could result in poor metabolizer ability; administration of inducers could improve metabolism.

Poor Metabolizers

Increased risk of toxicity from non-prodrugs due to lack of metabolism. Unlikely to benefit from prodrugs* due to reduced formation of active metabolites.

Easy-To-Read Results

Results are in an easy-to-read report that are color coded to alert prescribers when a dose adjustment or alternative drug should be considered. Once your patients know their genetic test results, they are more likely to take their medications or therapies as prescribed.
Personalized medicine reports provide data for Cardiology, Pain Management, Psychiatry and Urology specialists.

Resources
(1) Tennant, Forest, MD, DPH, Making Practical Sense of Cytomchrome P450, Practical Pain Management 10, no. 4 (May 2010)(2) US Food and Drug Administration Development Resources, Preventable Adverse Reactions: A Focus on Drug Interactions.(3) Peter D Hart Research Associates, American Talk about Pain: A Survey Among Adults Nationwide (August 2003):7